hotspot -WSS

hotspot

author：explore 2025-09-28 19:25:41 - browse：42274

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Streamlined flu vaccines recommended by FDA advisory panel

hotspot

explore

Wikipedia

WSS

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

$1 billion proposal to grow Boston, Massachusetts biotech

Stem cell biologist probes earliest stages of human development

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Microsoft's Peter Lee: Generative AI could help doctors be more human

Wikipedia

hotspot

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The UK government moves asylum

Apple is now the first public company to be valued at $3 trillion

Families look for replacement for GSK asthma drug Flovent

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

At least 12 people were injured in a blast at a port in northwest Turkey

How to save PrEP access — and even expand it

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Drug repurposing or repositioning? The language matters

Pregnant women don't need prenatal multivitamins, study concludes

focus

Mississippi candidates for statewide offices square off in party primaries

Longer MASH drug regimen improved liver, Akero study finds

Medicare drug price negotiation continues, as pharma counteroffers

At least 12 people were injured in a blast at a port in northwest Turkey

Trump Jan. 6 attorney John Lauro is ex

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

hotspot

explore

Wikipedia

explore